Abstract
Purpose
The optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. This study was performed to identify the differences in toxicity and completion rates of various chemotherapy protocols with that goal in mind.
Materials and methods
A total of 61 patients with esophageal cancer were enrolled in this study between June 2002 and January 2004. The total radiotherapy dose was 64 Gy. Three chemotherapy protocols were used. Arm A comprised daily low-dose cisplatin (CDDP) and 5-fluorouracil (5FU) (CF protocol) (3 mg/m2 and 180 mg/m2, respectively). Arm B was intermediate between arm A and C (CDDP 7 mg/m2 and 5FU 250 mg/m2 on days 1–5, 8–12, 29–33, and 36–40). Arm C comprised two courses of standard CF (CDDP 70 mg/m2 on day 1 and 5FU 600 mg/m2/24 h on days 1–4).
Results
Although there were no significant differences in hematological toxicity between the protocols, leukocytopenia was slightly milder in arm A. Nausea was significantly more severe in arm C. The completion rate was higher in arm A. The 3-year survival rates were 40%, 31%, and 62%, respectively.
Conclusion
The daily low-dose CF protocol showed a trend of mild toxicity regarding leukocytopenia. However, we could not find statistical difference between arms. It also showed a better completion rate than the other two arms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01); Radiation Therapy Oncology Group. JAMA 1999;281:1623–1627.
Araujo CM, Souhami L, Gil RA, Carvalho R, Garcia JA, Froimtchuk MJ, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991;67:2258–2261.
Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326: 1593–1598.
Smith TJ, Ryan LM, Douglass HO Jr, Haller DG, Dayal Y, Kirkwood J, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:269–276.
Hsu CH, Yeh KH, Lui LT, Lee YC, Bu CF, Wang HP, et al. Concurrent chemoradiotherapy for locally advanced esophageal cancer: a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 1999;19:4463–4467.
Sakai K, Inakoshi H, Sueyama H, Oda J, Ito T, Tsuchida E, et al. Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in operable esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1995;31:921–927.
Itoh Y, Fuwa N, Matumoto A, Asano A, Sasaoka M. Concurrent chemoradiotherapy using protracted infusion of low-dose CDDP and 5-FU and radiotherapy for esophageal cancer. Nippon Acta Radiol 1999;59:395–401.
Sasamoto R, Seki K, Inatoshi H, Sueyama H, Saito M, Sugita T, et al. Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP). Int J Clin Oncol 2007;12:25–30.
Sai H, Mitsumori M, Yamauchi C, Araki N, Okumura S, Nagata Y, et al. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 2004;9:149–153.
Nemoto K, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Saito H, et al. A pilot study of radiation therapy combined with daily low-dose cisplatin for esophageal cancer. Oncol Rep 2001;8:785–789.
Saji S, Aiba K, Araki H, Sasaki K, Shirasaka T, Sowa M, et al. Current status of low-dose CDDP: 5-FU therapy for solid malignant tumors-nationwide questionnaire survey. Jpn J Cancer Chemother 1997;24:1892–1900.
Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17:2915–2921.
Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999;43:517–523.
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–1174.
Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003;57:425–433.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s11604-009-0363-y
About this article
Cite this article
Sakayauchi, T., Nemoto, K., Ishioka, C. et al. Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer. Jap J Radiol 27, 131–137 (2009). https://doi.org/10.1007/s11604-008-0309-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-008-0309-9